|drug1757||Ivermectin nasal Wiki||0.50|
|drug292||Aspirin 81 mg Wiki||0.50|
|D004211||Disseminated Intravascular Coagulation NIH||0.22|
|D014808||Vitamin D Deficiency NIH||0.16|
There are 4 clinical trials
COVID-19 infection is overwhelming Italian healthcare. There is an urgent need for a solution to the lack of ICU beds and increasing deaths day after day. A recent retrospective Chinese paper (JAMA Intern Med, online March 13, 2020) showed impressive positive effect of methylprednisolone (MP) on survival of SARS-CoV-2 critically ill patients. Moreover, the Italian Infectious Disease leading institution guidelines for COVID-19 clinical management included as an option for patients with "incipient worsening of respiratory functions" methylprednisolone treatment at an approximate dose of 80mg. The main objective of this multi-centre observational trial is to analyse the association of low dose prolonged infusion of methylprednisolone (MP) for patients with severe acute respiratory syndrome with composite primary end-point (ICU referral, need for intubation, in-hospital death at day 28).
Description: We reported below the number of participants meeting at least one of three among death or ICU admission or Invasive mechanical ventilation.Measure: Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28 Time: 28 days
Description: We reported below the number of participants who died within 28 days, during the hospital stay.Measure: In-hospital Death Within 28 Days Time: 28 days
Description: We reported below the number of participants admitted to ICU within 28 days.Measure: Admission to Intensive Care Unit (ICU) Time: 28 days
Description: We reported below the number of participants who needed endotracheal intubation during ICU admissionMeasure: Endotracheal Intubation (Invasive Mechanical Ventilation) Time: 28 days
Description: Change in C-reactive protein after 7 days from baseline. A reduction of CRP reveals a laboratory improvement.Measure: Change in C-reactive Protein (CRP) Time: 7 days
Description: number of days free from mechanical ventilation (both invasive and non-invasive) by day 28Measure: Number of Days Free From Mechanical Ventilation Time: 28 days
19 COVID (Coronavirus disease 2019 ) is a deadly viral disease that has been spreading around the world for several months, and is caused by a CORONA family virus (COVID-19). Following IN-VITRO evidence of the antiviral effect of CHLOROQUINE in CORONA viruses, this drug has been used empirically for COVID-19 patients and is currently recommended in Israel for the treatment of intermediate and severity disease. The mechanism of action of chloroquine is in part by inhibiting the virus distribution, and changing the intracellular acidity, the virus distribution site. The intracellular chloroquine concentration is determined by a pump called PGP (permeability glycoprotein) that removes the drug from the cell and is activated by the drug. In the treatment of malaria, the benefit of low dosage of the drug has been shown to be effective due to the fact that the intracellular concentration of the drug is probably higher, and therefore the logic to examine this issue in COVID-19 treatment. The purpose of this study is to test whether a low dose of Chloroquine will reduce the duration of the viral shedding and prevent the disease from worsening.
Description: change in the extent and duration of virus shedding.Measure: change in virus duration (viral shedding) Time: 23 days
Description: change in the number of patients going from asymptomatic to moderately diseaseMeasure: change in the number of patients going from asymptomatic to moderately disease Time: 1 month
Facing the challenge of finding an efficient treatment for COVID-19, the viral pneumonia caused by the Coronavirus SARS-Cov-2, this study intended to test if Chloroquine or Hydroxychloroquine, two drugs with strong in-vitro antiviral role proven by numerous studies and with a well defined safety profile established, for efficacy in treating COVID-19 and improving an ordinal primary outcome composed by a 9-levels scale, which was recomended by the World Health Organization.
Description: Evaluation of the clinical status of patients on the 14th day after randomization defined by the 9-levels ordinal scale, with lower scores meaning better outcomes.Measure: World Health Organization (WHO) 9-levels ordinal scale (from 0-8) Time: 14 days after randomization
Description: Evaluation of the clinical status of patients on the 5th, 7th, 10th and 28th day after randomization defined by the 9-levels ordinal scale, with lower scores meaning better outcomes.Measure: World Health Organization (WHO) 9-levels ordinal scale (from 0-8) Time: 5, 7, 10 and 28 days after randomization
Description: All-cause mortality at 28 days after randomizationMeasure: Mortality Time: 28 days after randomization
Description: Number of days without need of Mechanical Ventilation at 28 days after randomizationMeasure: Ventilation free days Time: 28 days after randomization
Description: ICU Lenght of Stay on survivors at 28 days after randomizationMeasure: ICU Lenght of Stay Time: 28 days after randomization
Description: Hospital Lenght of Stay on survivors at 28 days after randomizationMeasure: Hospital Lenght of Stay Time: 28 days after randomization
Description: Acute Kidney Disease incidence measured by Kidney Disease Improving Global Outcomes (KDIGO) stage 3 sometime until the 28th day after randomization.Measure: Acute Kidney Disease incidence Time: 28 days after randomization
Description: Percentage of patients needing dialysis sometime until the 28th day.Measure: Percentage of patients needing dialysis Time: 28 days after randomization
Description: Presence of coagulopathy sometime until the 28th day (platelets < 150000 and/or INR >1.5 and/or KPTT > 35 seconds).Measure: Coagulopathy incidence Time: 28 days after randomization
Description: Mean of C Reactive Protein Levels on the 5th, 7th, 10th, 14th and 28th day after randomization, during period of hospitalizationMeasure: Mean of C Reactive Protein Levels Time: 5, 7, 10, 14 and 28 days after randomization
Description: Sequential Organ Failure Assessment (SOFA) scores (range, 0-24, with higher scores indicating greater organ dysfunction) on the 5th, 7th, 10th, 14th and 28th day after randomization, during period of hospitalization.Measure: Sequential Organ Failure Assessment (SOFA) scores Time: 5, 7, 10, 14 and 28 days after randomization
Description: Neutrophils/lymphocytes ratio on the 5th, 7th, 10th, 14th and 28th day after randomization, during period of hospitalization.Measure: Neutrophils/lymphocytes ratio Time: 5, 7, 10, 14 and 28 days after randomization
Description: Safety outcome: Any kind of arrhythmia identified by the attending physician at the time of the intercurrence, confirmed by an electrocardiogram (ECG), sometime until the 28th dayMeasure: Arrhythmia Time: 28 days after randomization
The global escalation of COVID19 pandemic has put the health care system under pressure with urgent need for treatment. In the absence of vaccine and approved drug against SARS-COV2 over the past 6 months, the health authorities were obliged to re-purpose existing drugs to fight this pandemic.
Description: Negative PCR result of SARS-Cov2 RNA in COVID19 patientsMeasure: PCR of SARS-Cov2 RNA Time: 14 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports